Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-paclitaxel conjugate

Takashi Oyama, Hiroya Takeuchi, Sachiko Matsuda, Soji Ozawa, Masaki Kitajima, Yuukou Kitagawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Although sentinel node (SN) biopsy has been applied for various types of solid tumors, its clinical significance is currently limited to the field of diagnostics. We developed a new translymphatic chemotherapy approach using a novel phospholipid polymer (PMB30W), which facilitates the dissolution of large amounts of paclitaxel. The purpose of the present study was to investigate the pharmacokinetics and antitumor effect of this conjugate (PTX-PMB30W) in a rat model. Materials and Methods: PTX-PMB30W was directly administered into the cecal submucosa or through the tail vein. The antitumor effect was compared between the two groups. Results: Paclitaxel concentrations in SNs remained constant over a 24-h period after local administration. Tumor growth was clearly suppressed by submucosal administration of PTX-PMB30W, resulting in a survival benefit compared to intravenous administration. Conclusion: Translymphatic chemotherapy targeting SNs via direct administration of PTX-PMB30W appears feasible, and this strategy may be applicable to the multi-disciplinary management of early solid cancer.

Original languageEnglish
Pages (from-to)1751-1758
Number of pages8
JournalAnticancer Research
Volume34
Issue number4
Publication statusPublished - 2014 Apr 1

Fingerprint

Paclitaxel
Phospholipids
Polymers
Drug Therapy
Neoplasms
Intravenous Administration
Tail
Veins
Pharmacokinetics
poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate)
Sentinel Lymph Node
Biopsy
Growth

Keywords

  • 2-methacryloyloxyethyl phosphorylcholine
  • Micrometastasis
  • Paclitaxel
  • Sentinel node
  • Translymphatic chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-paclitaxel conjugate. / Oyama, Takashi; Takeuchi, Hiroya; Matsuda, Sachiko; Ozawa, Soji; Kitajima, Masaki; Kitagawa, Yuukou.

In: Anticancer Research, Vol. 34, No. 4, 01.04.2014, p. 1751-1758.

Research output: Contribution to journalArticle

Oyama, T, Takeuchi, H, Matsuda, S, Ozawa, S, Kitajima, M & Kitagawa, Y 2014, 'Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-paclitaxel conjugate', Anticancer Research, vol. 34, no. 4, pp. 1751-1758.
Oyama, Takashi ; Takeuchi, Hiroya ; Matsuda, Sachiko ; Ozawa, Soji ; Kitajima, Masaki ; Kitagawa, Yuukou. / Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-paclitaxel conjugate. In: Anticancer Research. 2014 ; Vol. 34, No. 4. pp. 1751-1758.
@article{56d902e8da874f0da651924225c001e7,
title = "Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-paclitaxel conjugate",
abstract = "Background: Although sentinel node (SN) biopsy has been applied for various types of solid tumors, its clinical significance is currently limited to the field of diagnostics. We developed a new translymphatic chemotherapy approach using a novel phospholipid polymer (PMB30W), which facilitates the dissolution of large amounts of paclitaxel. The purpose of the present study was to investigate the pharmacokinetics and antitumor effect of this conjugate (PTX-PMB30W) in a rat model. Materials and Methods: PTX-PMB30W was directly administered into the cecal submucosa or through the tail vein. The antitumor effect was compared between the two groups. Results: Paclitaxel concentrations in SNs remained constant over a 24-h period after local administration. Tumor growth was clearly suppressed by submucosal administration of PTX-PMB30W, resulting in a survival benefit compared to intravenous administration. Conclusion: Translymphatic chemotherapy targeting SNs via direct administration of PTX-PMB30W appears feasible, and this strategy may be applicable to the multi-disciplinary management of early solid cancer.",
keywords = "2-methacryloyloxyethyl phosphorylcholine, Micrometastasis, Paclitaxel, Sentinel node, Translymphatic chemotherapy",
author = "Takashi Oyama and Hiroya Takeuchi and Sachiko Matsuda and Soji Ozawa and Masaki Kitajima and Yuukou Kitagawa",
year = "2014",
month = "4",
day = "1",
language = "English",
volume = "34",
pages = "1751--1758",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-paclitaxel conjugate

AU - Oyama, Takashi

AU - Takeuchi, Hiroya

AU - Matsuda, Sachiko

AU - Ozawa, Soji

AU - Kitajima, Masaki

AU - Kitagawa, Yuukou

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Background: Although sentinel node (SN) biopsy has been applied for various types of solid tumors, its clinical significance is currently limited to the field of diagnostics. We developed a new translymphatic chemotherapy approach using a novel phospholipid polymer (PMB30W), which facilitates the dissolution of large amounts of paclitaxel. The purpose of the present study was to investigate the pharmacokinetics and antitumor effect of this conjugate (PTX-PMB30W) in a rat model. Materials and Methods: PTX-PMB30W was directly administered into the cecal submucosa or through the tail vein. The antitumor effect was compared between the two groups. Results: Paclitaxel concentrations in SNs remained constant over a 24-h period after local administration. Tumor growth was clearly suppressed by submucosal administration of PTX-PMB30W, resulting in a survival benefit compared to intravenous administration. Conclusion: Translymphatic chemotherapy targeting SNs via direct administration of PTX-PMB30W appears feasible, and this strategy may be applicable to the multi-disciplinary management of early solid cancer.

AB - Background: Although sentinel node (SN) biopsy has been applied for various types of solid tumors, its clinical significance is currently limited to the field of diagnostics. We developed a new translymphatic chemotherapy approach using a novel phospholipid polymer (PMB30W), which facilitates the dissolution of large amounts of paclitaxel. The purpose of the present study was to investigate the pharmacokinetics and antitumor effect of this conjugate (PTX-PMB30W) in a rat model. Materials and Methods: PTX-PMB30W was directly administered into the cecal submucosa or through the tail vein. The antitumor effect was compared between the two groups. Results: Paclitaxel concentrations in SNs remained constant over a 24-h period after local administration. Tumor growth was clearly suppressed by submucosal administration of PTX-PMB30W, resulting in a survival benefit compared to intravenous administration. Conclusion: Translymphatic chemotherapy targeting SNs via direct administration of PTX-PMB30W appears feasible, and this strategy may be applicable to the multi-disciplinary management of early solid cancer.

KW - 2-methacryloyloxyethyl phosphorylcholine

KW - Micrometastasis

KW - Paclitaxel

KW - Sentinel node

KW - Translymphatic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84902261463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902261463&partnerID=8YFLogxK

M3 - Article

C2 - 24692706

AN - SCOPUS:84902261463

VL - 34

SP - 1751

EP - 1758

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -